top of page

Christophe Deben
Dec 5, 20241 min read
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays
At DrugVision.ai , we're committed to pushing the boundaries of organoid drug screening by integrating cutting-edge technologies into our...
420

Christophe Deben
Jan 23, 20241 min read
Auranofin Repurposing for Lung and Pancreatic Cancer: Low CA12 Expression as a Marker of Sensitivity in Patient-Derived Organoids, with Potentiated Efficacy by AKT Inhibition.
This study embarked on an ambitious journey, utilizing twenty 384-well microplates, exploring 11 drug synergy combinations, and analyzing...
350

Christophe Deben
Jan 23, 20242 min read
Single-organoid analysis reveals clinically relevant treatment-resistant and invasive subclones in pancreatic cancer
In this translational study, we explore pancreatic ductal adenocarcinoma (PDAC) and its inherent treatment resistance, emphasizing the...
110

Christophe Deben
Jan 23, 20242 min read
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
In this publication, we introduce an innovative drug screening methodology using patient-derived tumor organoids. This paper focuses on...
280

Christophe Deben
Jan 23, 20242 min read
OrBITS: label-free and time-lapse monitoring of patient derivedorganoids for advanced drug screening
In our original manuscript, we delve into the foundational work behind the development of the OrBITS label-free organoid detection...
330
bottom of page